Download PDF
Diabetologie und Stoffwechsel 2011; 6(4): 225-232
DOI: 10.1055/s-0031-1271569
Originalarbeit

© Georg Thieme Verlag KG Stuttgart ˙ New York

Einfluss der Stoffwechselverbesserung durch Pioglitazon auf die Herzratenvariabilität (HRV) bei Patienten mit Typ-2-Diabetes

Influence of Metabolic Improvement by Pioglitazone on Heart Rate Variability (HRV) in Patients with Type 2 DiabetesM.  Schönauer†, 1 , U. Schönauer1 , C. Kautz2 , H. Thiele3 , A. Thomas4
  • 1Diabetologische Schwerpunktpraxis, Leipzig
  • 2Asklepios Klinikum Weißenfels, Klinik für Innere Medizin
  • 3Universität Leipzig, Herzzentrum Kardiologie
  • 4Medtronic GmbH, Geschäftsbereich Diabetes, Meerbusch
Further Information

Publication History

Publication Date:
12 August 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In der vorliegenden multizentrischen Praxis­beobachtung wurden konsekutiv hausärztlich ­betreute Patienten mit Typ-2-Diabetes, einer Diabetesanamnese unter 4 Jahren und mit antidia­betischen Behandlung ohne Insulin einer kardio­vaskulären Risikostratifizierung unterzogen und mittels Spektralanalyse der Herzratenvariabilität (HRV) auf das Vorliegen einer kardialen auto­nomen diabetischen Neuropathie (KADN) untersucht. Nachfolgend wurde bei 227 Patienten über einen Zeitraum von 12 Monaten die Veränderung der HRV unter dem Einfluss des Insulinsensiti­zers Pioglitazon ermittelt und mit Stoffwechsel- und Kreislaufparametern korreliert. Dabei zeigten sich eine signifikante Verbesserung der HRV und der Stoffwechsel- und Kreislaufparameter. Zum Vergleich wurden 88 Patienten ohne Glitazon­behandlung auf die gleiche Weise untersucht. Bei diesen Patienten ließ sich keine Verbesserung der HRV zeigen. Die gewonnenen Daten zeigen, dass die Messung der HRV mittels Spektralanalyse eine gute Methode ist, um in der hausärztlichen Praxis aus der Klientel der Typ-2-Diabetiker Hoch-Risiko-Patienten zu identifizieren und um eine adäquate präventive Therapie einzuleiten. 

Abstract

In this open multicenter user observation, patients with type 2 diabetes, diabetes duration < 4 years, without insulin therapy were recruited by general practitioners with the aim of stratification for cardiovascular risk. Laboratory param­eters of metabolic control, blood pressure and ­heart rate variability (HRV) were determined. ­Investigated was the influence of pioglitazone on these parameters during 12 months in 227 patients. For comparison, a group with 88 diabetics without glitazone was investigated. Under pio­glitazone therapy a significant increasing of HRV and a improvement of metabolic control were observed, which was not evident in the group with­out pioglitazone. This investigation showed that the spectral analysis of HRV is a suitable method for the detection of high risk patients with cardiovascular autonomic diabetic neuropathy, which then can receive closer follow-up and a more sufficient medical therapy. 

Schlüsselwörter

Screening in Hausarztpraxen - Typ-2-Diabetes - kardiale autonome diabetische Neuropathie (KADN) - Herzratenvariabiliät (HRV) - modifizierter Orthostasetest - Pioglitazon

Key words

general practitioners - cardiovascular autonomic diabetic neuropathy (CADN) - heart rate variability (HRV) - modified orthostase test - pioglitazone

Literatur

  • 1 Hauner H. Diabetesepidimie und Dunkelziffer. Deutscher Gesundheitsbericht Diabetes Verlag Kirchheim; 2011: 8-13
    Google Scholar
  • 2 Hauner H, Köster I, von Ferber L. Ambulante Versorgung von Patienten mit Diabetes mellitus im Jahr 2001.  Dtsch Med Wochenschr. 2003;  128 2638-2643
    Article in Thieme ConnectGoogle Scholar
  • 3 Liebl A, Neuß A, Spannheimer A et al. Kosten des Typ-2-Diabetes in Deutschland: Ergebnisse der CODE-2-Studie.  Dtsch Med Wochenschr. 2001;  126 585-589
    Article in Thieme ConnectGoogle Scholar
  • 4 Haslbeck M, Luft D, Neundörfer B et al. Deutsche Evidenz-basierte Diabetes-Leitlinie der DDG – Diskussionsentwurf Diagnose und Therapie der antonomen diabetischen Neuropathien.  Diabetes und Stoffwechsel. 2001;  12 1113-1132
    Google Scholar
  • 5 Dekker J M, Schouten E G, Klootwijk P et al. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study.  Am J Epidemiol. 1997;  145 899-908
    CrossrefPubMedGoogle Scholar
  • 6 Liao D, Cai J, Rosamond W D. Cardiac autonomic function and incident coronary heart disease: A population-based case-cohort study: The ARIC study.  Am J Epidemiol. 1997;  145 696-706
    CrossrefGoogle Scholar
  • 7 Tsuji H, Venditti F J, Manders E S et al. Reduced heart rate variability and mortality risk in an elderly cohort: The Framingham heart study.  Circulation. 1994;  90 878-883
    CrossrefGoogle Scholar
  • 8 Gerritsen J, Dekker J M, TenVoorde B J et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease. The HOORN Study.  Diabetes Care. 2001;  24 1793-1798
    CrossrefPubMedGoogle Scholar
  • 9 Maser R E, Mitchell B D, Vinik A I et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes. A meta-analysis.  Diabetes Care. 2003;  26 1895-1901
    CrossrefPubMedGoogle Scholar
  • 10 Navarro X, Kennedy W R, Aeppli D et al. Neuropathy and mortality in diabetes: influence of pancreas transplantation.  Muscle Nerve. 1996;  19 1009-1016
    CrossrefGoogle Scholar
  • 11 Valensi P, Sachs R N, Harfouche B. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia.  Diabetes Care. 2001;  24 339-343
    CrossrefGoogle Scholar
  • 12 O’Brien I A, O’Hare J P, Lewin I G et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability.  J Med. 2001;  61 957-967
    Google Scholar
  • 13 Carke B F, Ewing D J, Campbell I W. Diabetic autonomic neuropathy.  Diabetologia. 1979;  17 195-212
    CrossrefGoogle Scholar
  • 14 Maser R E, Pfeifer M A, Dorman J S et al. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III.  Arch Intern Med. 1990;  150 1218-1222
    CrossrefGoogle Scholar
  • 15 Cohen J A, Jeffers B W, Faldut D et al. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM).  Muscle Nerve. 1998;  21 72-80
    CrossrefGoogle Scholar
  • 16 Gill V A, Woodward A, Casson I F et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes-the “dead in bed” syndrome revisited.  Diabetologia. 2009;  52 42-45
    CrossrefGoogle Scholar
  • 17 The ACCORD Study group . Effects of Intensive Glucose Lowering in Type 2 Diabetes.  N Engl J Med. 2008;  358 2545-2559
    CrossrefGoogle Scholar
  • 18 Howorka K, Pumprla J, Haber P et al. Effects of physical training on heart rate variability in diabetic patients with various degrees of car­diovascular autonomic neuropathy.  Cardiovasc Res. 1997;  34 206-214
    CrossrefGoogle Scholar
  • 19 Boulton A JM, Venik A L, Arezzo J C et al. Diabetic Neuropathies, A statement by the American Diabetes Association.  Diabetes Care. 2005;  28 956-962
    CrossrefGoogle Scholar
  • 20 Singh J P, Larson M G, O’Donnell C J et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study).  Am J Cardiol. 2000;  86 309-312
    CrossrefPubMedGoogle Scholar
  • 21 DCCT Research Group . The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT).  Diabetologia. 1998;  41 416-423
    CrossrefGoogle Scholar
  • 22 Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
    Google Scholar
  • 23 Schönauer M, Thomas A, Kautz C et al. Diabetiker mit kardiovaskulärem Risiko identifizieren mit Herzratenvariabilitätsmessung.  Diabetes, Stoffwechsel und Herz. 2008;  17 161-168
    Google Scholar
  • 24 Howorka K, Pumprla J, Schabmann A. Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy.  J Auton Nerv Syst. 1998;  69 164-172
    CrossrefGoogle Scholar
  • 25 Ewing D J. Cardiovascular reflexes and autonomic neuropathy.  Clin Sci Med. 1978;  55 321-327
    Google Scholar
  • 26 Aronson D, Burger A J. Effect of beta-blockade on heart rate variability in decompensated heart failure.  Intl J Cardiol. 2001;  79 31-39
    CrossrefGoogle Scholar
  • 27 Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology . Heart rate variability – standards of measurement, physiological interpretation, and clinical use.  Eur Heart J. 1996;  17 354-381
    CrossrefGoogle Scholar
  • 28 Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.  Diabetes Care. 2000;  23 1605-1611
    CrossrefGoogle Scholar
  • 29 Schernthaner G, Matthews D R, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.  J Clin Endocrinol Metab. 2004;  89 6068-6076
    CrossrefGoogle Scholar
  • 30 Mathisen A, Egan J, Schneider R. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes. Pioglitazone 010 Study Group.  Diabetes. 1999;  48 A106
    CrossrefGoogle Scholar
  • 31 Füchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.  Exp Clin Endocrinol Diabetes. 2000;  108 151-163
    Article in Thieme ConnectGoogle Scholar
  • 32 King A B. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.  Diabetes Care. 2000;  23 557
    Google Scholar
  • 33 Dormandy J A, Charbonnel B, Eckland D J et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.  Lancet. 2005;  366 1279-1289
    CrossrefPubMedGoogle Scholar
  • 34 Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.  J Clin Endocrinol Metab. 2002;  87 2784-2791
    CrossrefGoogle Scholar
  • 35 Tsuji H, Larson M G, Venditti Jr F J et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study.  Circulation. 1996;  94 2850-2855
    CrossrefGoogle Scholar
  • 36 Rathmann W, Ziegler D, Jahnke M et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy.  Diabet Med. 1993;  10 664-671
    CrossrefGoogle Scholar
  • 37 O’Brien I A, McFadden J P, Corrall R J. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes.  Q J Med. 1991;  79 495-502
    Google Scholar
  • 38 Ziegler D, Dannehl K, Mühlen H et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy.  Diabet Med. 1992;  9 806-814
    CrossrefGoogle Scholar
  • 39 Ewing D J, Martyn C N, Young R J et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes.  Diabetes Care. 1985;  8 491-498
    CrossrefPubMedGoogle Scholar
  • 40 Sampson M J, Wilson S, Karagiannis P et al. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics.  Q J Med. 1990;  75 635-646
    Google Scholar
  • 41 Nilsson H, Bergstrom B, Lilja B et al. Prospective study of autonomic nerve function in type 1 and type 2 diabetic patients: 24 hour heart rate variation and plasma motilin levels disturbed in parasympathetic neuropathy.  Diabet Med. 1995;  12 1015-1021
    CrossrefGoogle Scholar
  • 42 DCCT Research Group . The effect of intensive diabetes therapy on the development and progression of neuropathy.  Ann Intern Med. 1995;  122 561-568
    Google Scholar

Dr. med. U. Schönauer

Diabetologische Schwerpunktpraxis

August-Bebel-Str. 71

04275 Leipzig

Phone: 03 41 / 3 03 26 37

Fax: 03 41 / 3 03 26 38

Email: MSchoenauer@web.de

      >